<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The genetic background may modify the individual's risk of developing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We performed a case-control study to test the impact of genomic polymorphisms of 9 genes involved in <z:chebi fb="0" ids="35703">xenobiotics</z:chebi> detoxification and DNA repair in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Frequencies of polymorphic variants of RAD51, XRCC3, NQO1, GSTA1, GSTM1, GSTT1, CYP3A4 and <z:e sem="disease" ids="C0268138" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">XPD</z:e> enzymes were similar in patients and controls </plain></SENT>
<SENT sid="3" pm="."><plain>On the other hand, the GSTP1-105Val allele was associated to an increased risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (O.R </plain></SENT>
<SENT sid="4" pm="."><plain>1.66; p=0.04) and to higher probability of overall survival in the low/intermediate-1 IPSS risk group (p=0.008) </plain></SENT>
<SENT sid="5" pm="."><plain>The GSTP1-Ile105Val polymorphism is likely to influence <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> risk and prognosis </plain></SENT>
</text></document>